Jane Street
CRSP icon

Jane Street’s CRISPR Therapeutics CRSP Stock Holding History

Jane Street’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Buy
+3,780
New +$199K ﹤0.01% 10069
2025
Q2 		– Sell
-237,128
Closed -$9.18M – 9786
2025
Q1 		$8.07M Sell
237,128
-189,689
-44% -$8.04M ﹤0.01% 2270
2024
Q4 		$16.8M Buy
426,817
+255,387
+149% +$12.1M ﹤0.01% 1409
2024
Q3 		$8.05M Sell
171,430
-178,501
-51% -$9.06M ﹤0.01% 2160
2024
Q2 		$18.9M Buy
349,931
+174,859
+100% +$10.1M ﹤0.01% 1367
2024
Q1 		$11.9M Sell
175,072
-299,936
-63% -$21.5M ﹤0.01% 1648
2023
Q4 		$29.7M Buy
475,008
+349,887
+280% +$19.3M 0.01% 972
2023
Q3 		$5.68M Buy
125,121
+28,650
+30% +$1.48M ﹤0.01% 2438
2023
Q2 		$5.42M Sell
96,471
-37,739
-28% -$2.14M ﹤0.01% 2615
2023
Q1 		$6.07M Buy
134,210
+63,620
+90% +$3.09M ﹤0.01% 2188
2022
Q4 		$2.87M Buy
70,590
+64,020
+974% +$3.4M ﹤0.01% 3290
2022
Q3 		$429K Sell
6,570
-104,845
-94% -$7.6M ﹤0.01% 6963
2022
Q2 		$6.77M Buy
111,415
+24,436
+28% +$1.44M ﹤0.01% 2229
2022
Q1 		$5.46M Sell
86,979
-206,099
-70% -$12.9M ﹤0.01% 2892
2021
Q4 		$22.2M Buy
293,078
+43,882
+18% +$3.83M 0.01% 1126
2021
Q3 		$27.9M Sell
249,196
-162,965
-40% -$20.5M 0.01% 906
2021
Q2 		$66.7M Buy
412,161
+47,075
+13% +$5.73M 0.03% 433
2021
Q1 		$44.5M Buy
365,086
+180,737
+98% +$27.3M 0.02% 537
2020
Q4 		$28.2M Buy
184,349
+175,906
+2,083% +$20.8M 0.01% 677
2020
Q3 		$706K Buy
8,443
+3,549
+73% +$315K ﹤0.01% 4646
2020
Q2 		$360K Sell
4,894
-21,656
-82% -$1.27M ﹤0.01% 5562
2020
Q1 		$1.13M Buy
26,550
+20,485
+338% +$1.06M ﹤0.01% 2669
2019
Q4 		$370K Buy
+6,065
New +$331K ﹤0.01% 4039
2019
Q3 		– Sell
-11,907
Closed -$561K – 5149
2019
Q2 		$561K Buy
11,907
+5,646
+90% +$226K ﹤0.01% 3431
2019
Q1 		$224K Sell
6,261
-33,013
-84% -$1.14M ﹤0.01% 4545
2018
Q4 		$1.12M Sell
39,274
-48,352
-55% -$1.68M ﹤0.01% 2395
2018
Q3 		$3.89M Buy
87,626
+77,674
+780% +$4.07M 0.01% 1249
2018
Q2 		$585K Sell
9,952
-9,421
-49% -$537K ﹤0.01% 3421
2018
Q1 		$886K Buy
+19,373
New +$800K ﹤0.01% 2818

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street's CRSP Position: Q2 2026 in Review

Jane Street opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 3,780 shares worth $206K. The stake represents ﹤0.01% of the portfolio and ranks #10069 among its holdings. This is a return to the name: Jane Street previously reported a position in CRSP as recently as Q1 2025.

Jane Street first reported a position in CRSP in Q1 2018 and has held it in 29 quarters since. The position peaked at $66.7M in Q2 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Jane Street held 3,780 shares of CRISPR Therapeutics worth $206K as of Q2 2026.
  • CRISPR Therapeutics was a new Jane Street position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10069 holding.
  • Jane Street first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 29 quarters since.
  • Jane Street's CRISPR Therapeutics position peaked at $66.7M in Q2 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.